Get in touch
Our Client Services team is on hand to help. Please call us at 866.776.5907, Option 3.
Estrogen Receptor (ER) belongs to a superfamily of nuclear hormone receptors and is expressed in about 85% of invasive breast cancers. There are two known isoforms of estrogen receptor, ERα and ERβ. It is a weak prognostic factor but a strong predictive factor for response to endocrine therapies, both in adjuvant and metastatic settings. The primary indication to assess ER in breast cancer is to predict response to hormonal therapies such as tamoxifen, other selective estrogen receptor modulators (SERMs) and aromatase inhibitors. In univariate analysis, moderate to strong staining in even 1% of the invasive tumor cells is associated with significant improvement in disease-free survival compared to those patients whose tumor lacks ER expression.
*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.
Last Updated: August 12, 2025